Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Are we halted ?
View:
Post by maxonfire on Jan 26, 2023 12:35pm

Are we halted ?

I wish we were !
Comment by ramrodretired on Jan 26, 2023 1:00pm
Yes, Strange this time aday and NO volume! GOOD OR BAD?
Comment by Legit62 on Jan 26, 2023 1:11pm
I put buy order  in wouldnt take
Comment by chry200030 on Jan 26, 2023 1:11pm
We are just waiting on FDA approval news now.  Then we balst off.  How long? a week, a month or 6 months., but it will come.
Comment by wearethebest on Jan 26, 2023 1:20pm
Yes and if this was a US company it would already would have FDA approval.This is something that could save a lot of peoples lives and this is stupit  on their part don't you think.
Comment by fredgoodwinson on Jan 26, 2023 1:48pm
Agree WATB that this would have had approval by now if it were a US Company - probably some time ago (and first line in an early stage setting - a far bigger market). Whether this represents stupidity on their part is another matter. 
Comment by ScienceFirst on Jan 26, 2023 4:44pm
What type of reasoning is this??? FDA approvals have to be based on data.  Not on air.   It happends that we just reached 1.5 months ago the milestone (450-days data on 25 patients) that was requested by the FDA at the time of the design of the Ph. 2 trial.  And that was for the BCG-Unresponsive market. The same that want rigor are the ones that want to skip steps because ...more  
Comment by fredgoodwinson on Jan 26, 2023 4:58pm
This reasoning is in the context of a belief (which I strongly expressed at the time of the Clinical Protocol) that on the basis of the preclinical evidence TLD-1433 deserved to be trialled as a first-line treatment against early stage disease. Many lesser prospects had and have been permitted this setting.
Comment by gebremeskel on Jan 26, 2023 5:18pm
Your belief about how TLD-1433 "deserved" to be trialled is beside the point. Did Theralase request this of the FDA and were not "permitted"? Or did Theralase submit the exact protocol they wanted to - for BCG-unresponsive NMIBC? 
Comment by enriquesuave on Jan 26, 2023 5:26pm
1st line would require a head to head trial of about 500 patients vs BCG in a randomized control trial. IMO. Much more lengthy and costly.  Now we can potentially be used off label as a 1st line treatment, as well as for unresponsive BCG when hopefully approved.  IMHO 
Comment by fredgoodwinson on Jan 26, 2023 6:50pm
If Enrique is correct as to the likely number of triallists required then accept that first-line/early stage would not have been feasible on the grounds of cost unless partnered.
Comment by ScienceFirst on Jan 26, 2023 5:42pm
Wrong, unless you can provide real examples. It is not the way drug approvals have ever worked (starting from early staging).  It has always been the opposite, for obvious reasons, as drugs that have never been tested could represent a risk. The FDA, with its FrontRunner program, wants to accelerate the venue of late-stage drugs faster to early stage.  But once again, these drugs must ...more  
Comment by Rumpl3StiltSkin on Jan 26, 2023 5:41pm
So SF, At this point is it likely, or even possible, that TLT has applied for BTD. Or are we still likely waiting on clinicians to crunch the CR data on these first 25?
Comment by ScienceFirst on Jan 26, 2023 5:46pm
Rump ... Very difficult to call.  It all depends on how many people are involved in the process.  
Comment by enriquesuave on Jan 26, 2023 6:27pm
My guess is that if Dr Kulkarni who is the principal Investigator is presenting data mid February, then for sure by then we should have all stats needed for both  FDA and Poster presentation.  At least IMHO.    
Comment by ScienceFirst on Jan 26, 2023 6:33pm
Enrique ... After looking at the abstract conditions last night, there are some things that cannot be included.  Like efficacy %s, for example.  It's really regulated. Please refer to my post of yesterday, 01:04pm. Soon after Feb., we might be able to see what might look like this poster, if no ASCO rules prohibit that.
Comment by gebremeskel on Jan 26, 2023 3:00pm
Sorry, that doesn't make any sense. Whether you're from Timbuctu or the good ol' USA, before you can get FDA approval you need to submit a minimum amount of clinical data as evidence of safety and efficacy. We haven't done that until just now! As my old pal Charlie Drake once sang, "If you want your boomerang to come back, well, first you've got to throw it!"
Comment by Oilminerdeluxe on Jan 26, 2023 1:20pm
I suspect volume will be a bit different then...
Comment by Rumpl3StiltSkin on Jan 26, 2023 1:32pm
Strange
Comment by Kingpin68 on Jan 26, 2023 1:56pm
My small order was confirmed by my bank. Hasn't changed he volume from zero yet though.
Comment by O12009 on Jan 26, 2023 2:38pm
No shares has traded on TSX but 28 thousand has traded on the other exchanges.
Comment by RetiredREX on Jan 26, 2023 2:54pm
Any idea how to confirm whether halted or not?
Comment by StevenBirch on Jan 26, 2023 3:21pm
Almost always when a stock is halted the bid and ask will be the same unless it's a stock with literally no activity. And I think we are stuck here until the next release because if the sell-off was PP related there has to be enough of a spread to make it worth it to sell, looks like $0.30 was the lowest, and no one will bid it up just to have the same people come in and knock it down again ...more  
Comment by stocksnbonds458 on Jan 26, 2023 3:24pm
A lot of my small caps are not showing trading today, a glitch??
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250